Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback